anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:The titled remedy containing an Fc fragment of human gamma globulin. CONSTITUTION:A remedy for diseases (e.g., collagen disease such as systemic lupus erythematosus, rheumatoid arthritis, etc., protopathic glomerulonephritis, etc.) caused by deposition of antigen-antibody complex on cell and tissue, containing a free Fc fragment, one waste of human gamma globulin, as an active ingredient. By administrating it, the complex is dissolved or eliminated, the cause of the disease is removed, to cure it radically. Administration path is intravenous medication, and intramuscular medication or partial administration to the affected part is also possible. A standard dose is 5-30mg/kg/day, by intravenous administration continuously for 1- several weeks.
Pruritus is often accompanied with bacterial infections, but the underlying mechanism is not fully understood. Although previous studies revealed that lipopolysaccharides (LPS) could directly activate TRPV4 channel and TRPV4 is involved in the generation of both acute itch and chronic itch, whether and how LPS affects TRPV4-mediated itch sensation remains unclear. Here, we showed that LPS-mediated TRPV4 sensitization exacerbated GSK101-induced scratching behaviour in mice. Moreover, this effect was compromised in TLR4-knockout mice, suggesting LPS acted through a TLR4-dependent mechanism. Mechanistically, LPS enhanced GSK101-evoked calcium influx in mouse ear skin cells and HEK293T cells transfected with TRPV4. Further, LPS sensitized TRPV4 channel through the intracellular TLR4-PI3K-AKT signalling. In summary, our study found a modulatory role of LPS in TRPV4 function and highlighted the TLR4-TRPV4 interaction in itch signal amplification.
PROBLEM TO BE SOLVED: To enable hair to be set quickly, easily, and securely by giving solution of a substance containing a mercapto group to hair. SOLUTION: When ultrasonic vibration is given to hair 2 to set the hair 2 using a hair setter 4, solution of a substance containing a mercapto group is given to the hair 2. As a substance containing a mercapto group, the protein component contained in the hair 2 can be preferably used, for instance, cysteine can be used. Mercaptobenzoic acid also can be used. The solution of a substance containing a mercapto group can be given, for instance, by applying the solution to the hair 2. It is allowed to give ultrasonic vibration to the hair 2 after applying the solution to the hair 2, or otherwise to apply the solution of a substance containing a mercapto group giving ultrasonic vibration to the hair 2. After drying the hair 2 applied with the solution of a substance containing a mercapto group, ultrasonic vibration can be given to the hair 2.
Subjects will receive a single dose of GSK525762 10 mg on day 1. From day 3 to 17 inclusive, subjects will receive a single dose of 600 mg rifampicin in fasting conditions. On day 18 subjects will receive single dose of GSK525762 either 20 or 30 mg along with 600 mg dose of rifampicin. On day 19 subjects will receive a single dose of rifampicin 600 mg.
Tryptophan (Trp) is an essential amino acid, whose metabolism is a key gatekeeper of intestinal homeostasis. Yet, its systemic effects, particularly on atherosclerosis, remain unknown. Here we show that high-fat diet (HFD) increases the activity of intestinal indoleamine 2, 3-dioxygenase 1 (IDO), which shifts Trp metabolism from the production of microbiota-derived indole metabolites towards kynurenine production. Under HFD, the specific deletion of IDO in intestinal epithelial cells leads to intestinal inflammation, impaired intestinal barrier, augmented lesional T lymphocytes and atherosclerosis. This is associated with an increase in serotonin production and a decrease in indole metabolites, thus hijacking Trp for the serotonin pathway. Inhibition of intestinal serotonin production or supplementation with indole derivatives alleviates plaque inflammation and atherosclerosis. In summary, we uncover a pivotal role of intestinal IDO in the fine-tuning of Trp metabolism with systemic effects on atherosclerosis, paving the way for new therapeutic strategies to relieve gut-associated inflammatory diseases.
The present invention relates to a recombinant immunotoxic for resisting tumor, its preparation method and application. Said invention constructs a target toxin fusion protein, it contains diphtherin amino acid fragment, vascular endo thelial growth factor amino acid fragment and intermediate connecting peptide. The preparation method of said fusion protein includes the following steps: 1). constructing plasmid containing target; 2). transferring said plasmid into colibacillus to make expression; 3). centrifugally-collecting somatic, ultrasonic cracking, washing to obtain crude inclusion body; and 4). dialysis, ion exchange and gel filtration.
The 'AIR-test', a method wherein inspiratory oxygen concentration is reduced to 21% and pulse-oximetry hemoglobin saturation (SpO2) is monitored, can be used to demonstrate the presence of an atelectasis-induced alveolar shunt. It remains uncertain whether an intraoperative positive AIR-test is associated with clinical outcomes. It is hypothesized that in a general surgical population, the incidence of postoperative pulmonary complications (PPC) is higher in patients with a positive AIR-test than in patients with a negative AIR-test. The aim of this study is to describe the incidence of PPC in patients with a positive and in patients with a negative AIR-test. Second, the investigators want to describe the incidence of a positive AIR-test and its association with the development of PPC. The investigators also want to evaluate whether mechanical ventilation strategy differs between patients with a positive and negative AIR-test.
BACKGROUND: Patients with fibro-calcific aortic valve disease (FCAVD) have lipid depositions in their aortic valve that engender a proinflammatory impetus toward fibrosis and calcification and ultimately valve leaflet stenosis. Although the lipoprotein(a)-autotaxin (ATX)-lysophosphatidic acid axis has been suggested as a potential therapeutic target to prevent the development of FCAVD, supportive evidence using ATX inhibitors is lacking. We here evaluated the therapeutic potency of an ATX inhibitor to attenuate valvular calcification in the FCAVD animal models.
METHODS: ATX level and activity in healthy participants and patients with FCAVD were analyzed using a bioinformatics approach using the Gene Expression Omnibus datasets, enzyme-linked immunosorbent assay (ELISA), immunohistochemistry, and western blotting. To evaluate the efficacy of ATX inhibitor, interleukin-1 receptor antagonist-deficient (Il1rn-/-) mice and cholesterol-enriched diet-induced rabbits were used as the FCAVD models, and primary human valvular interstitial cells (VICs) from patients with calcification were employed.
RESULTS: The global gene expression profiles of the aortic valve tissue of patients with severe FCAVD demonstrated that ATX gene expression was significantly upregulated and correlated with lipid retention (r = 0.96) or fibro-calcific remodeling-related genes (r = 0.77) in comparison to age-matched non-FCAVD controls. Orally available ATX inhibitor, BBT-877, markedly ameliorated the osteogenic differentiation and further mineralization of primary human VICs in vitro. Additionally, ATX inhibition significantly attenuated fibrosis-related factors' production, with a detectable reduction of osteogenesis-related factors, in human VICs. Mechanistically, ATX inhibitor prohibited fibrotic changes in human VICs via both canonical and non-canonical TGF-β signaling, and subsequent induction of CTGF, a key factor in tissue fibrosis. In the in vivo FCAVD model system, ATX inhibitor exposure markedly reduced calcific lesion formation in interleukin-1 receptor antagonist-deficient mice (Il1rn-/-, P = 0.0210). This inhibition ameliorated the rate of change in the aortic valve area (P = 0.0287) and mean pressure gradient (P = 0.0249) in the FCAVD rabbit model. Moreover, transaortic maximal velocity (Vmax) was diminished with ATX inhibitor administration (mean Vmax = 1.082) compared to vehicle control (mean Vmax = 1.508, P = 0.0221). Importantly, ATX inhibitor administration suppressed the effects of a high-cholesterol diet and vitamin D2-driven fibrosis, in association with a reduction in macrophage infiltration and calcific deposition, in the aortic valves of this rabbit model.
CONCLUSIONS: ATX inhibition attenuates the development of FCAVD while protecting against fibrosis and calcification in VICs, suggesting the potential of using ATX inhibitors to treat FCAVD.
In clinical trials, there have been uncommon cases of serious hepatic reactions during treatment with voriconazole (including clinical hepatitis, cholestasis and fulminant hepatic failure, including fatalities). Instances of hepatic reactions were noted to occur primarily in patients with serious underlying medical conditions (predominantly hematological malignancy). Hepatic reactions, including hepatitis and jaundice, have occurred among patients with no other identifiable risk factors. Liver dysfunction has usually been reversible on discontinuation of therapy [see Adverse Reactions (6.1)].

  


A higher frequency of liver enzyme elevations was observed in the pediatric population [see Adverse Reactions (6.1)]. Hepatic function should be monitored in both adult and pediatric patients.

  


Measure serum transaminase levels and bilirubin at the initiation of voriconazole therapy and monitor at least weekly for the first month of treatment. Monitoring frequency can be reduced to monthly during continued use if no clinically significant changes are noted. If liver function tests become markedly elevated compared to baseline, voriconazole should be discontinued unless the medical judgment of the benefit/risk of the treatment for the patient justifies continued use [see Dosage and Administration (2.5) and Adverse Reactions (6.1)].
Patients randomized to the sham treatment will receive the sham device on postoperative day (POD) 1 or day of extubation, whichever comes first. Patients will be seen on POD #1 by a blinded physiotherapist (PT) for mobility and education on supported coughing. The sham group will also be instructed to complete 15 breaths twice per waking hour in a seated position and receive education on proper use of the device. The sham device is identical in exterior appearance to the OPEP device but does not contain the internal mechanism providing expiratory pressure. As such, the device will be set to the highest setting and will not need to be adjusted at all for patient tolerance. The PT will reassess the patients on POD 2 and 3 to assess for proper technique and continued use of the device, as well as usual care. Patients will use the OPEP device up to POD#5 pressure settings and compliance will be recorded and measure by use of a daily log.
PURPOSE: To obtain a poly(orthoester) which contains a therapeutic agent and can release the therapeutic agent in an optimal environment by mixing a polyol with a ketene acetal contg. a functional group, incorporating a therapeutic agent into the mixture, and polymerizing the mixture.  
     CONSTITUTION: A polyol (pref. 1,2,3,4,5,6-hexanehexanol or the like) is mixed with a keteneacetal having two or more functional groups (e.g. a compd. of formula I), a therapeutic agent is incorporated into the mixture, and the mixture is polymerized. Thus, a poly(orthoester) [e.g. a compd. of formula II (wherein n is 335)] contg. a therapeutic agent is rapidly prepd. at a low temp. without heating, distillation and the like and without preparing any by-product. Since the above reaction is carried out at a low temp., it is possible to prevent the decomposition of the therapeutic agent. 
     COPYRIGHT: (C)1990,JPO
<P>PROBLEM TO BE SOLVED: To provide a light irradiation apparatus for rheumatism treatment which is easy to handle without taking the risk of side reaction by a biological formulation.  <P>SOLUTION: Joint-related cells centering on macrophage 3 are irradiated with treatment light 12 from a light emitting element and at least the production of IL-1β(8) and IL-6(10) produced from the joint-related cells is suppressed. By that, by suppressing the surplus production of TNF-α(9) and IL-1β(8) happening inside the joint of a patient suffering from rheumatism by irradiating a joint part with light, inflammation is suppressed. That is, since the production of TNT-α(9) of the whole body is not suppressed, various kinds of side reaction due to lack of TNF-α(9) observed in infliximab treatment do not occur. In the meantime, in the aspect of treatment costs, an expensive chemical is not used, a light source not to be reduced from use is repeatedly used, and thus an inexpensive treatment method is provided.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Device assisted enteroscopy (DAE) like the double balloon enteroscopy (DBE) and single balloon enteroscopy (SBE) are postulated to ease small bowel examination and performance of therapy. However, studies comparing the effectiveness of these 2 modalities have yielded varying results. The aim of this study is to compare the efficacy and safety of SBE and DBE. We retrospectively reviewed records of patients who underwent DBE (n = 82) or SBE (n = 45) for small bowel exam in our unit from January 2014 to January 2022. Our primary outcomes were to compare the technical success and diagnostic success rates between DBE and SBE. Our secondary outcomes were to compare the therapeutic success, and complication rates. The main indications were suspected GI bleeding (DBE 41.5% vs SBE 48.9%), iron deficiency anemia (DBE 9.8% vs SBE 4.4%) and small bowel lesions (DBE 28.0% vs SBE 44.4%) detected either from prior capsule endoscopy or radiological imaging. Majority of the enteroscopy exam was by antegrade approach (DBE 67.1% vs SBE 77.8%). We found no significant difference in the technical success (DBE 95.1% vs SBE 97.8%, P = .46), diagnostic success (DBE 69.5% vs SBE 77.8%, P = .36) and the therapeutic success rate (DBE 63.2% vs SBE 54.3%, P = .09) between the groups. Complications occurred in 1 case from each group (mucosal tear). None of the complications were major. In patients who underwent enteroscopy, the diagnostic and therapeutic performance of SBE is similar to DBE. Both procedures were safe with low complication rates.
Pembrolizumab will be administered at a dose of 200 mg as an IV infusion through a freely flowing IV. The diluted solution will be administered intravenously over 30 minutes through an intravenous line containing a sterile, non-pyrogenic, low-protein binding 0.2 micron to 5 micron in-line or add-on filter. Other drugs will not be co-administered through the same infusion line. Pembrolizumab doses will be repeated every three weeks.
. The study\&#39;s sample size will be 26 participants. Inclusion criteria for this study will be: Diagnosed Autistic between ages 4-10 years, Diagnosed Autistic Children, Treatment was given to each of the participants for 3 days a week and for 8 weeks. Inclusion criteria were all gender with the age group of 4-10 years, participants diagnosed cases of Autism spectrum disease with Toe Walking and their exclusion criteria were suspected but undiagnosed cases of ASD, the presence of any limb deformities , autistic children with MR, and unwillingness of participant or parents to be a part of the study. An RCT included 26 diagnosed autistic children as per inclusion criteria the subjects were divided into two groups, i.e., group A and B, the group A was given MET with Stationary bicycling whereas Group B was given MET without Stationary Bi-Cycling participants were clinically examined. Dynamometer, foot posture Index, Observational Gait Scale, and Parent report of percentage of time toe walking,
A medical media and medical device ecommerce system comprising a software platform that operates on computing devices connected through a network. Medical professionals and other qualified individuals, and member of the general public can establish accounts on the system through client computer terminals. Value Media, media having intellectual value to other clinicians or to members of the public is onboarded, IP validated, and stored on the system and available for purchase by other medical professionals and members of the public using an ecommerce module in the system that rewards authors of the uploads. A consortium module provides peer review of the value media by others so qualified. A job board module provides to match and schedule medical professionals and those seeking medical treatment according to various filters for in-home treatment or treatment sessions at cooperative service centers. The system also provides an integrated system for CE testing and credit.
BACKGROUND: Chronic opioid use is associated with problematic opioid use, such as opioid abuse. It is important to develop a prediction model for safe opioid use. In this study, we aimed to develop and validate a risk score model for chronic opioid use in opioid-naïve, noncancer patients, using data from a nationwide database.
METHODS: Data from the National Health Insurance Claims Database in the Republic of Korea from 2016 to 2018 were used, and adult, noncancer patients who were started on non-injectable opioid analgesics (NIOAs) were included. The risk score model was developed using the β coefficient of each variable in the multivariable logistic regression analysis.
RESULTS: Overall, 676,676 noncancer patients were started on NIOAs, of which 65,877 (9.7%) were prescribed NIOAs chronically. Age, baseline healthcare utilization, comorbidities, co-medications, and pattern of first NIOA prescription were identified as risk factors for chronic opioid use. The c-static for the performance of our risk score model was 0.754 (95% confidence interval, 0.750-0.758).
CONCLUSION: To our knowledge, this is the first tool that can predict chronic opioid use in the Korean population. The model can help physicians examine the risk of chronic opioid use by patients who are started on NIOA.
PURPOSE: To provide a fibrinogen preparation excellent in solubility by adding a specific solubilizing auxiliary agent, and a fibrin glue kit using the same and capable of obtaining sufficient adhesiveness. CONSTITUTION: This fibrinogen preparation can completely dissolve to form an aqueous solution of 1w/v% or higher concentration in a shortened time, preferably more than 4w/v% within 6 minutes. This preparation is obtained by adding, as a solubilizing auxiliary, 0.2-5 pts.wt., preferably 0.5-2wt.% of a nonionic surfactant, preferably polyoxyethylene-polyoxypropylene copolymer of 5,900-12,500 molecular weight, per 100 pts.wt. of fibrinogen. It is preferred that 1-100 pts.wt. of human serum albumen, 5-200 pts.wt. of sugar or sugar alcohol (preferably xylitol) and 5-200 pts.wt. of an amino acid, preferably arginine are added in order to further increase the solubility of this preparation.
Sulfasalazine salt compositions are provided. In some cases, the sulfasalazine salts have a crystalline form. The subject crystalline sulfasalazine salts can provide a water soluble form of the active compound that finds use in pharmaceutical compositions and therapeutic applications. The subject crystalline sulfasalazine salts can provide increased solubility as compared to the zwitterionic or free acid form of sulfasalazine. Also provided are pharmaceutical compositions including the subject sulfasalazine salt compositions. Methods of treating a neurological related disease such as refractory epilepsy using the subject crystalline sulfasalazine salts and pharmaceutical compositions are also provided.
After observation discovery, the cancer of esophagi is a disease initiated by pathogenic cold and food accumulation, and extraneous observation and operation observation have consistent results. Using (radish, gingers and corainder) soup for treating patients has good effect, thereby summarizing traditional Chinese medicine for treating cancer of esophagi. During treatment, the traditional Chinese medicine has an effect on the patients capable of drinking decoctions of medicinal ingredients. For the patients inserted with stomach tubes, the traditional Chinese medicine also has effect after entering stomachs by pouring the decoctions of medicinal ingredients into the stomach tubes. For the patients with constipations, the decoctions of medicinal ingredients are poured into the stomachs from the stomach tubes and then can make defecation normal after 4-5 days. Patients with obstructed esophagi are most afraid of generating phlegm, thus doctors need to be prepared for phlegm extraction.
Cannabidiol for use in the treatment of epilepsy, wherein the epilepsy is a treatment-resistant epilepsy (TRE), and wherein the TRE is Tuberous Sclerosis complex (TSC), is provided. Preferably the TSC is characterised by both complex partial seizures and generalised seizures or primarily by complex partial seizures. Preferably the CBD is used in combination with one or more concomitant anti-epileptic drugs (AED) which may be selected from the group consisting of clobazam, levetiracetam, topiramate, stiripentol, phenobarbital, lacsamide, valproic acid, zonisamide, perampanel and fosphenytoin, wherein the dose of anti-epileptic drug/s that is/are used in combination with the CBD is reduced. Preferably the CBD is present as a highly purified extract which comprises at least 98% (w/w) CBD. Preferably the extract further comprises up to 1% CBDV (cannabidivarin) and less than 0.15% THC (tetrahydrocannabinol). Preferably the dose of CBD is from 5mg/kg/day to 25mg/kg/day.
The qigong intervention consists of 1 hour/week qigong classes for 12 weeks to be delivered virtually. The first 2 weeks will include 2 hours/week classes. In addition, each participant will be instructed to practice qigong at home for 90 minutes.
The present invention provides a Bcl-2-interacting protein. This Bcl-2-interacting protein has been purified and shown to be identical to a previously described 28 kDa protein (p28) called Bap31 /CDM. Human p28 is a polytopic integral protein of the endoplasmic reticulum (ER) whose cytosolic domain contains overlapping death effector domain and leucine zipper homologies, flanked on either side by identical caspase recognition sites. Following apoptotic stimuli in the absence of Bcl-2, p28 was cleaved at both caspase recognition sites. One of the cleavage products, p20, caused induction of apoptosis when expressed ectopically in otherwise normal cells. All of these events were prevented by elevated expression of Bcl-2. p28 Bap31 may be a Bcl-2-regulated component of an apoptosis signaling pathway, perhaps involving coordinated ER-mitochondrial events. P28 Bap31 itself or the cleavage of p28 Bap31 and the cleavage products thereof are useful in diagnostic kits, laboratory reagents, assays and development of reagents for the treatment of disease relating to apoptosis.